Benzinga | Apr 13, 2021 07:31AM EDT

Geron Announces First Patient Dosed In IMpactMF Phase 3 Clinical Trial In Refractory Myelofibrosis

Geron Corporation (NASDAQ:GERN) today announced that the first patient has been dosed in IMpactMF, the Phase 3 clinical trial evaluating imetelstat, a first-in-class telomerase inhibitor, in refractory myelofibrosis (MF).